Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).

Biogen and Ionis Pharma announced that Spinraza (nusinersen) met its primary endpoint in its Phase III trial in later-onset spinal muscular atrophy (SMA).